{"id":"W3185045240","doi":"10.1007/s41669-021-00286-3","title":"Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Imatinib; Internal medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Tyrosine kinase; Cost effectiveness; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001059093,0.0004915077,0.001223091,0.0001250618,0.0001443513,0.0000608286,0.0007236337,0.0001155395,0.0007566608],"category_scores_gemma":[0.00006767223,0.000359601,0.0003746422,0.00018147,0.0001723624,0.0002613243,0.0003341264,0.0002104519,0.00006308185],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01173801,"about_ca_system_score_gemma":0.005218507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00074425,"about_ca_topic_score_gemma":0.001843146,"domain_scores_codex":[0.9972417,0.0002411983,0.001006576,0.0008156723,0.0001446916,0.0005501422],"domain_scores_gemma":[0.9959984,0.002280819,0.0003667222,0.0009783122,0.0001821425,0.0001936418],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04082122,0.002581307,0.001447759,0.0009556944,0.009364856,0.0000591771,0.004657979,0.7393005,0.1495111,0.00203258,0.001844938,0.04742283],"study_design_scores_gemma":[0.07918715,0.003317201,0.004730876,0.0003011567,0.001661965,0.00004097597,0.0003694898,0.2530991,0.6500848,0.0002776345,0.006405055,0.0005246444],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814152,0.001732076,0.0001422117,0.001982078,0.000654266,0.01077169,0.001584406,0.00001703446,0.001701027],"genre_scores_gemma":[0.9935394,0.001540786,0.0003686789,0.0003497599,0.0002716962,0.00299251,0.0004347741,0.00009978498,0.0004026396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5005737,"threshold_uncertainty_score":0.9998856,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1007693090773644,"score_gpt":0.4117837647717765,"score_spread":0.3110144556944122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}